Display options
Cite
Elshafae SM, Kohart NA, Breitbach JT, et al. The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205066.
Elshafae, S. M., Kohart, N. A., Breitbach, J. T., Hildreth, B. E., & Rosol, T. J. (2021). The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors. Cancers, 13(20), . https://doi.org/10.3390/cancers13205066
Elshafae, Said M, et al. "The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205066
Elshafae SM, Kohart NA, Breitbach JT, Hildreth BE, Rosol TJ. The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors. Cancers (Basel). 2021 Oct 10;13(20). doi: 10.3390/cancers13205066. PMID: 34680215; PMCID: PMC8533796.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Oct 10;13(20). doi: 10.3390/cancers13205066.

The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors.

Cancers

Said M Elshafae, Nicole A Kohart, Justin T Breitbach, Blake E Hildreth, Thomas J Rosol

Affiliations

  1. Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
  2. Department of Pathology, Faculty of Veterinary Medicine, Benha University, Kalyubia 13736, Egypt.
  3. Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  4. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.

PMID: 34680215 PMCID: PMC8533796 DOI: 10.3390/cancers13205066

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an intractable disease affecting nearly 4% of Human T-cell Leukemia Virus Type 1 (HTLV-1) carriers. Acute ATL has a unique interaction with bone characterized by aggressive bone invasion, osteolytic metastasis, and hypercalcemia. We hypothesized that dual tumor and bone-targeted therapies would decrease tumor burden in bone, the incidence of metastasis, and ATL-associated osteolysis. Our goal was to evaluate dual targeting of both ATL bone tumors and the bone microenvironment using an anti-tumor HDACi (AR-42) and an osteoclast inhibitor (zoledronic acid, Zol), alone and in combination. Our results showed that AR-42, Zol, and AR-42/Zol significantly decreased the viability of multiple ATL cancer cell lines in vitro. Zol and AR-42/Zol decreased tumor growth in vivo. Zol ± AR-42 significantly decreased ATL-associated bone resorption and promoted new bone formation. AR-42-treated ATL cells had increased mRNA levels of

Keywords: AR-42; adult T-cell leukemia/lymphoma; bone; osteolysis; zoledronic acid

References

  1. Immunol Res. 2005;32(1-3):217-23 - PubMed
  2. Leuk Lymphoma. 1994 Aug;14(5-6):395-400 - PubMed
  3. Carcinogenesis. 2006 Apr;27(4):673-81 - PubMed
  4. Endocr Rev. 1998 Feb;19(1):18-54 - PubMed
  5. JCI Insight. 2019 Oct 3;4(19): - PubMed
  6. Blood. 2011 Aug 18;118(7):1736-45 - PubMed
  7. Int J Cancer. 2004 Nov 1;112(2):171-8 - PubMed
  8. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-6230s - PubMed
  9. Blood. 2005 Dec 15;106(13):4294-302 - PubMed
  10. Br J Haematol. 1991 Nov;79(3):428-37 - PubMed
  11. Bone. 2009 May;44(5):908-16 - PubMed
  12. Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 - PubMed
  13. Mol Cancer Ther. 2007 Nov;6(11):2976-84 - PubMed
  14. Clin Breast Cancer. 2010 Oct 1;10(5):359-66 - PubMed
  15. Mayo Clin Proc. 2008 Sep;83(9):1032-45 - PubMed
  16. Clin Microbiol Rev. 2010 Jul;23(3):577-89 - PubMed
  17. Oncotarget. 2017 Aug 27;8(41):69250-69263 - PubMed
  18. Invest New Drugs. 2010 Dec;28 Suppl 1:S3-20 - PubMed
  19. Neoplasia. 2016 Dec;18(12):765-774 - PubMed
  20. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8 - PubMed
  21. Immunity. 2012 Mar 23;36(3):491-501 - PubMed
  22. Blood. 2011 Sep 1;118(9):2483-91 - PubMed
  23. PLoS Pathog. 2011 Feb 10;7(2):e1001274 - PubMed
  24. Cancer Sci. 2015 Apr;106(4):344-51 - PubMed
  25. Cell Death Dis. 2013 Oct 24;4:e878 - PubMed
  26. N Engl J Med. 2004 Apr 15;350(16):1655-64 - PubMed
  27. Virology (Auckl). 2013 Nov 18;4:49-59 - PubMed
  28. Oncogene. 2013 Sep 5;32(36):4222-30 - PubMed
  29. Blood. 2002 Jan 15;99(2):634-40 - PubMed
  30. Blood. 2004 Aug 1;104(3):802-9 - PubMed
  31. Semin Oncol. 2001 Apr;28(2 Suppl 6):35-44 - PubMed
  32. Retrovirology. 2004 Aug 13;1:20 - PubMed
  33. Blood. 1999 Apr 1;93(7):2360-8 - PubMed
  34. J Clin Pathol. 2007 Dec;60(12):1373-7 - PubMed
  35. Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10309-14 - PubMed
  36. Viruses. 2015 Dec 30;8(1): - PubMed
  37. Int J Cancer. 2004 Apr 20;109(4):559-67 - PubMed
  38. Vet Pathol. 2010 Jul;47(4):677-89 - PubMed
  39. Prostate. 2017 May;77(7):776-793 - PubMed
  40. Leuk Res. 2011 Nov;35(11):1491-7 - PubMed
  41. PLoS Pathog. 2015 Sep 17;11(9):e1005142 - PubMed
  42. Arthritis Res Ther. 2007;9 Suppl 1:S5 - PubMed
  43. J Bone Oncol. 2019 Aug 20;19:100257 - PubMed
  44. Oncogene. 2005 Sep 5;24(39):6047-57 - PubMed
  45. Mol Cancer Ther. 2010 Dec;9(12):3210-20 - PubMed
  46. Int J Mol Sci. 2021 May 24;22(11): - PubMed
  47. Cancer Res. 2007 Dec 15;67(24):11859-66 - PubMed
  48. Gan. 1981 Dec;72(6):978-81 - PubMed
  49. J Clin Oncol. 2009 Jan 20;27(3):453-9 - PubMed
  50. Leuk Res. 2008 Feb;32(2):287-96 - PubMed
  51. Blood. 2013 Jun 20;121(25):5045-54 - PubMed
  52. AIDS. 2004 May 21;18(8):1101-8 - PubMed
  53. Leukemia. 2007 Aug;21(8):1752-62 - PubMed
  54. Mol Med. 2011 May-Jun;17(5-6):466-72 - PubMed
  55. Blood. 2017 Mar 2;129(9):1071-1081 - PubMed
  56. Leukemia. 1996 Feb;10(2):333-7 - PubMed
  57. Leukemia. 2005 Nov;19(11):1896-904 - PubMed
  58. Nat Rev Cancer. 2011 Jun;11(6):411-25 - PubMed
  59. Virology. 1996 Dec 15;226(2):167-75 - PubMed
  60. Prostate. 2014 Sep;74(13):1251-65 - PubMed
  61. Retrovirology (Auckl). 2015;7:1-5 - PubMed
  62. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 - PubMed
  63. J Bone Miner Res. 2004 Jul;19(7):1105-11 - PubMed
  64. Acta Pathol Jpn. 1986 Mar;36(3):349-62 - PubMed
  65. Leukemia. 2004 Aug;18(8):1357-63 - PubMed
  66. PLoS One. 2010 Jun 03;5(6):e10941 - PubMed
  67. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1976;19(3-4):273-7 - PubMed
  68. J Bone Miner Res. 1998 Apr;13(4):581-9 - PubMed
  69. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 - PubMed
  70. Am J Pathol. 2001 Jun;158(6):2219-28 - PubMed
  71. Leuk Lymphoma. 2010 Apr;51(4):702-14 - PubMed

Publication Types

Grant support